Management of hydroxyurea resistant or intolerant polycythemia vera
- Author(s)
- Raman, I; Pasricha, SR; Prince, HM; Yannakou, C;
- Journal Title
- Leukemia & Lymphoma
- Publication Type
- e409
- Abstract
- Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy are at the cornerstone of management. First line cytoreductive therapy in high-risk patients is hydroxyurea; however, its use is associated with toxicities and resistance in a significant proportion of patients. In a disease with a long overall survival with appropriate treatment, it is imperative that other treatment options do not accelerate the risk of progression to acute leukemia. The following review will appraise the evidence of interferon, ruxolitinib, and other agents in management of hydroxyurea resistant or intolerant polycythemia vera.
- Publisher
- Taylor & Francis
- Keywords
- PEGylated interferon alpha; Polycythemia vera; hydroxyurea resistance/intolerance; ruxolitinib
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 33949918
- Publisher's Version
- https://doi.org/10.1080/10428194.2021.1901092
- Open Access at Publisher's Site
https://doi.org/10.1080/10428194.2021.1901092- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-05-11 04:12:13
Last Modified: 2021-05-17 11:20:07